CA09073K1084
© Newsfile
23.12.2025
BUX
LISTED
CSE
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
News Preview
Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially init...
Themefolio
Profiler
Peergroup
© Newsfile
01.12.2025
BUX
LISTED
CSE
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
News Preview
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening PlatformVancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cance...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2025
BUX
LISTED
CSE
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
News Preview
Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosisVancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKD...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
07.10.2025
BUX
LISTED
CSE
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
News Preview
Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leadin...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
29.09.2025
BUX
LISTED
CSE
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
News Preview
Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technolog...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2025
BUX
LISTED
CSE
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
News Preview
Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone MarketsVancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strateg...
Themefolio
Profiler
Peergroup
© Newsfile
30.07.2025
BUX
LISTED
CSE
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year 2025 highlights and key milestones for 2025 - 2026. The Company's an...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2025
BUX
LISTED
CSE
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
News Preview
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities.Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2025
BUX
LISTED
CSE
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
News Preview
Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung DiseasesVancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biops...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2025
BUX
LISTED
CSE
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
News Preview
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platformVancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer dete...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2025
BUX
LISTED
CSE
BioMark Announces the Final Closing of Oversubscribed Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement.The closing of the seco...
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2025
BUX
LISTED
CSE
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the "Private Placement"...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
28.02.2025
BUX
LISTED
CSE
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025
News Preview
BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosisVancouver, British Columbia--(Newsfile Corp. - February 28, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, proudly joins today the g...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2024
BUX
LISTED
CSE
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
News Preview
BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast CancerVancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection, announced a significant advancement in its breast cancer diagnostic...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2024
BUX
LISTED
CSE
BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection
News Preview
BioMark Strengthens Liquid Biopsy Platform for Breast Cancer DetectionVancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced significant progress in its breast cancer program...
Themefolio
Profiler
Peergroup
© Newsfile
24.09.2024
BUX
LISTED
CSE
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
News Preview
BioMark's Liquid Biopsy Technology Offers Promise for NEN DiagnosisVancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is excited to announce that its latest work, has been published in Cancers, t...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2024
BUX
LISTED
CSE
BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
News Preview
Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer ScreeningVancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce today the successful completion of a...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2024
BUX
LISTED
CSE
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that Chief Executive Officer Rashid Bux and Chief Scientific Officer Jean-François Haince will participate in the upcom...
Themefolio
Profiler
Peergroup
© Newsfile
31.07.2024
BUX
LISTED
CSE
The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay
News Preview
The new patent granted by the USPTO strengthens and expands BioMark's global IP portfolio in liquid biopsy, enhancing cancer management solutions.Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - BioMark Diagnostics Inc., (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests f...
Themefolio
Profiler
Peergroup
© Newsfile
15.07.2024
BUX
LISTED
CSE
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long time collaborators at the University...
Themefolio
Profiler
Peergroup
© Newsfile
18.04.2024
BUX
LISTED
CSE
BioMark Announces Warrant Extension and Granting of Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that the Company intends to amend the terms of 5,062,000 the non-broker warr...
Themefolio
Profiler
Peergroup
© Newsfile
09.04.2024
BUX
LISTED
CSE
BioMark to Advance Development of Cancer Treatment for Glioblastoma
News Preview
The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study.Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect...
Themefolio
Profiler
Peergroup
© Newsfile
28.02.2024
BUX
LISTED
CSE
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce tod...
Themefolio
Profiler
Peergroup
© Newsfile
26.02.2024
BUX
LISTED
CSE
Theresa Peterson Joins Biomark's Advisory Team
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark's Advisory team. Mr. Rashid Ahmed...
Themefolio
Profiler
Peergroup
© Newsfile
29.12.2023
BUX
LISTED
CSE
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that it has closed a financing round to accelerate the commercializa...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2023
BUX
LISTED
CSE
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian...
Themefolio
Profiler
Peergroup
© Newsfile
28.11.2023
BUX
LISTED
CSE
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results from the second quarter ended September 30, 2023. Th...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2023
BUX
LISTED
CSE
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
News Preview
Dr. W. Randolph Ford, Ph.D., will be joining BioMark's Advisory team to support Artificial Intelligence and Machine Learning capabilities.Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to det...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2023
BUX
LISTED
CSE
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
News Preview
Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its wholly owned laboratory sub...
Themefolio
Profiler
Peergroup
© Newsfile
24.10.2023
BUX
LISTED
CSE
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
News Preview
Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark's liquid biopsy platform beyond early lung cancer detection.Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid...
Themefolio
Profiler
Peergroup
© Newsfile
30.08.2023
BUX
LISTED
CSE
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark's Advisory team to support it...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2023
BUX
LISTED
CSE
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
News Preview
New family of patent granted by Japanese Patent Office enhances BioMark's global intellectual property position in lung cancer detection using urine as a convenient biological sample medium.Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2023
BUX
LISTED
CSE
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 25, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity. The Company is unaware of any material chan...
Themefolio
Profiler
Peergroup
© Newsfile
05.06.2023
BUX
LISTED
CSE
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
News Preview
BioMark's blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting.Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat...
Themefolio
Profiler
Peergroup
© Newsfile
31.05.2023
BUX
LISTED
CSE
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
News Preview
The new family of patent granted by USPTO strengthens BioMark's global intellectual property position in liquid biopsy and early cancer detectionVancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to d...
Themefolio
Profiler
Peergroup
© Newsfile
03.05.2023
BUX
LISTED
CSE
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
News Preview
New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark's liquid biopsy platform, to be presented.Vancouver, British Columbia--(Newsfile Corp. - May 3, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy compan...
Themefolio
Profiler
Peergroup
© Newsfile
16.03.2023
BUX
LISTED
CSE
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this week suggests that Pulmonary Neuroendocrine Tumors...
Themefolio
Profiler
Peergroup
© Newsfile
01.03.2023
BUX
LISTED
CSE
BioMark Provides Third Quarter Operational Update and 2023 Outlook
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2022, as well as outlook for 2...
Themefolio
Profiler
Peergroup
© Newsfile
07.02.2023
BUX
LISTED
CSE
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc (...
Themefolio
Profiler
Peergroup
© Newsfile
11.01.2023
BUX
LISTED
CSE
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company's liquid b...
Themefolio
Profiler
Peergroup
© Newsfile
28.11.2022
BUX
LISTED
CSE
BioMark Provides Business Update and Second Quarter Financial Results
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the "Warrants")...
Themefolio
Profiler
Peergroup
© Newsfile
27.10.2022
BUX
LISTED
CSE
BioMark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2022
BUX
LISTED
CSE
The US Patent Office Grants BioMark Additional Patent for Its Liquid Biopsy Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2022
BUX
LISTED
CSE
BioMark to Present Validation Data of Its Multianalyte Metabolite Panel for Lung Cancer Screening at the ESMO Congress 2022
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it's abstract titled "Metabolomic Profiling for the Early Detection of Lung Cancer...
Themefolio
Profiler
Peergroup
© Newsfile
01.09.2022
BUX
LISTED
CSE
BioMark Selected by the Medical Alley and Investissement Quebec to Join the Us Go-To-Market Accelerator
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (...
Themefolio
Profiler
Peergroup
© Newsfile
30.08.2022
BUX
LISTED
CSE
BioMark Provides First-Quarter 2022 Financial Results and Operational Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 202...
Themefolio
Profiler
Peergroup
© Newsfile
14.07.2022
BUX
LISTED
CSE
BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-y...
Themefolio
Profiler
Peergroup
© Newsfile
21.06.2022
BUX
LISTED
CSE
BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that it has been successful in obt...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2022
BUX
LISTED
CSE
BioMark Diagnostics and the Icahn School of Medicine at Mount Sinai Announce Partnership to Advance Early Lung Cancer Screening Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that BioMark and the Icahn School of Medicine at Mount Sinai in New York (...
Themefolio
Profiler
Peergroup
© Newsfile
04.05.2022
BUX
LISTED
CSE
BioMark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of...
Themefolio
Profiler
Peergroup
© Newsfile
27.04.2022
BUX
LISTED
CSE
BioMark to Present New Cancer Screening Data Using the LDTD-MS/MS Technique at the Annual ASMS Conference on Mass Spectrometry
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Ann...
Themefolio
Profiler
Peergroup
© Newsfile
01.03.2022
BUX
LISTED
CSE
BioMark Provides the Third Quarter Operational Update and 2022 Outlook
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2021."We closed out the quarte...
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2022
BUX
LISTED
CSE
BioMark to Present at the Virtual Biotech Showcase and the Digital RESI JPM 2022 Conferences
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS")...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2021
BUX
LISTED
CSE
BioMark participera avec Astrazeneca, Pfizer Canada et la Fondation de l'IUCPQ à un projet de 3,5 m$ pour améliorer la détection précoce du cancer du poumon
News Preview
Vancouver, British Columbia--(Newsfile Corp. - 30 novembre 2021) - BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2021
BUX
LISTED
CSE
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS")...
Themefolio
Profiler
Peergroup
© Newsfile
25.11.2021
BUX
LISTED
CSE
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, today reports its operational update for the second quarter ended September 30, 2021. The Company...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2021
BUX
LISTED
CSE
BioMark obtiens un financement pour accélérer le développement de sa technologie de biopsie liquide au Québec
News Preview
Vancouver, British Columbia--(Newsfile Corp. - 16 novembre 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark»), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer qu...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2021
BUX
LISTED
CSE
BioMark Secures Funding to Accelerate Development of Its Liquid Biopsy Assay in Quebec
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS")., is receivi...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2021
BUX
LISTED
CSE
BioMark Recognizes and Supports the Lung Cancer Awareness Month
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a dia...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2021
BUX
LISTED
CSE
Diagnostic and Therapeutic Benefits of BioMark's Cancer Marker Featured in Two Poster Presentations at the Canadian Cancer Research Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the diagnostic and therapeutic capabilities of its SSAT cancer marker will be featured i...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
